ClinicalTrials.gg
CompletedNCT00107939Updated Mar 22, 2017

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

A Phase 3 interventional study of Licarbazepine in Bipolar Disorder, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
46th of 704
453 · median 58
Started
2004
with 41 others
Phase 3
117 of 837
3 open now
Registered
64th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 46th largest by enrollment of the 704 interventional ones that give a count, is one of 42 that started in 2004, is one of 117 in phase 3, and was the 64th registered.

Bipolar Disorder

1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder. The investigational drug will be given as additional therapy to one of the five following medications: risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole. These medications are already FDA (Food and Drug Administration)-approved treatments for mania.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • bipolar disorder
  • manic episode
  • treatment
  • licarbazepine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bipolar disorder (type I) with manic or mixed episodes (including patients with/without psychotic features or with/without a history of rapid cycling)
  • In need of psychiatric treatment
  • Cooperation and willingness to complete all aspects of the study

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis other than bipolar I disorder
  • History of schizophrenia or schizoaffective disorder
  • Drug dependence within 1 month prior to study start or testing positive in a urine drug test
  • Suicide attempt within 1 month prior to study start or at immediate risk of harm to self or others
  • Any form of psychotherapy within 1 month prior to study start
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
453 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (week 6)

Secondary outcomes

  1. Safety and tolerability of treatment with licarbazepine over 6 weeks, with respect to adverse events and SAEs, laboratory values, ECGs and vital signs.

07

Study locations

22 sites
  • Investigational Site
    Little Rock, Arkansas 72201, United States
  • Investigational Site
    Orange, California 92868, United States
  • Investigational Site
    Pico Rivera, California 90660, United States
  • Investigational Site
    San Diego, California 92108, United States
  • Investigational Site
    San Diego, California 92126, United States
  • Investigational Site
    Boca Raton, Florida 33432, United States
  • Investigational Site
    Atlanta, Georgia 30308, United States
  • Investigational Site
    Chicago, Illinois 60640, United States
  • Investigational Site
    Joliet, Illinois 60435, United States
  • Investigational Site
    Indianapolis, Indiana 46222, United States
  • Investigational Site
    Topeka, Kansas 66606, United States
  • Investigational Site
    Kansas City, Missouri 64133, United States
  • Investigational Site
    St. Louis, Missouri 63104, United States
  • Invetigational Site
    Brooklyne, New York 11201, United States
  • Investigational Site
    Cedarhurst, New York 11516, United States
  • Investigational Site
    New York, New York 10003, United States
  • Investigational Site
    Cincinnati, Ohio 45267, United States
  • Investigational Site
    Columbus, Ohio 43210, United States
  • Investigational Site
    Providence, Rhode Island 02903, United States
  • Investigational Site
    Bellaire, Texas 77401, United States
  • Investigational Site
    Bellevue, Washington 98004, United States
  • Investigational Site
    West Allis, Wisconsin 53227, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2005
First posted
Apr 12, 2005
Start
Nov 2004
Primary completionActual
Apr 2007
CompletionActual
Apr 2007
Last update
Mar 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00107939
Responsible party
Sponsor
First posted
Apr 12, 2005
Start date
Nov 2004
Primary completion
Apr 2007
Completion
Apr 2007
Last update
Mar 22, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Licarbazepine

Start the discussion